LEXICON PHARMACEUTICALS INC (LXRX)

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Confirms Previously Disclosed and Anticipated FDA Decision

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Confirms Previously Disclosed and Anticipated FDA Decision...

Wednesday's session: top gainers and losers

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule Top-line Data...

Lexicon Pharmaceuticals to Participate in December Investor Conferences

Lexicon Pharmaceuticals to Participate in December Investor Conferences

THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including...

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions Prioritizing Strong R&D...

Lexicon Appoints Ivan H. Cheung to Board of Directors

Lexicon Appoints Ivan H. Cheung to Board of Directors

THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected...

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

Study results add to the growing body of evidence differentiating sotagliflozin within SGLT inhibitor class...

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory...

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

People with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin (HbA1c), the primary endpoint, as people...

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

PDUFA target action date set for December 20, 2024...

Notable Wednesday Option Activity: SNOW, MDB, LXRX

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

Post hoc analysis evaluated sotagliflozin in patients with diabetic kidney disease (DKD)...

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

-Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments...

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

/PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon...

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing...

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief...

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin   TIR measures approach target set by...

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will...

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista

Advisory Committee Meeting Scheduled for October 31, 2024; PDUFA Goal Date Remains December 20, 2024 Lexicon Seeks Approval for ZYNQUISTA™...